Senior Correspondent, London
Ben's Feed
Nov 17, 2014

Pfizer dampens Astra bid hopes with German Merck cancer deal

FRANKFURT/LONDON (Reuters) – Pfizer (PFE.N: Quote, Profile, Research) dampened investors’ expectations of a renewed bid for AstraZeneca (AZN.L: Quote, Profile, Research) on Monday by signing a major cancer drug deal with Germany’s Merck KGaA (MRCG.DE: Quote, Profile, Research), reducing the U.S. firm’s need for Astra’s products.

Merck will get an upfront payment of $850 million (544 million pounds) from the U.S. drugmaker for sharing rights to develop its experimental immunotherapy drug with Pfizer. It is also eligible for up to $2 billion in payments based on the medicine’s future success.

Nov 17, 2014

Pfizer dampens Astra bid hopes by signing German Merck cancer deal

FRANKFURT/LONDON (Reuters) – Pfizer (PFE.N: Quote, Profile, Research, Stock Buzz) punctured investor expectations of a renewed bid for AstraZeneca (AZN.L: Quote, Profile, Research, Stock Buzz) on Monday by signing a major cancer drug deal with Germany’s Merck KGaA (MRCG.DE: Quote, Profile, Research, Stock Buzz), reducing the U.S. firm’s need for Astra’s products.

Merck will get an upfront payment of $850 million from the U.S. drugmaker for sharing rights to develop its experimental immunotherapy drug with Pfizer. It is also is eligible for up to $2 billion in payments based on the medicine’s future success.

Nov 17, 2014

Corruption tars drug industry drive to improve access for poor

LONDON, Nov 17 (Reuters) – The world’s top drugmakers have
improved access to medicines in developing countries, according
to a report on Monday, but their good work is undermined by a
sorry record of unethical behaviour.

The Access to Medicines Index, which ranks the 20 leading
pharmaceutical companies every two years on how well they get
treatments to the poor, said the industry’s progress had been
“uneven”.

Nov 13, 2014

AstraZeneca developing reversal agent for heart drug Brilinta

LONDON, Nov 13 (Reuters) – AstraZeneca is developing
an antibody treatment to reverse the blood-thinning effect of
its heart drug Brilinta in rare emergency situations, such as
urgent surgery or in the event of major bleeding.

The move could give Brilinta an edge among drugs that block
platelets in the blood, since there are no approved products to
counteract their effects. Because they reduce clotting, the
drugs can cause problems if doctors need to operate suddenly.

Nov 11, 2014
Nov 10, 2014
Nov 10, 2014
Nov 10, 2014
Nov 7, 2014
Nov 6, 2014
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben